You are viewing a Web site, archived on 00:51:51 Oct 17, 2004. It is now a Federal record managed by the National Archives and Records Administration.
External links, forms, and search boxes may not function within this collection.
[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
Powered by Google

National Recruitment Efforts Underway for
Director of Oncology Drug Products in CDER’s Office of New Drugs

The U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), is seeking a highly skilled and dedicated individual to serve as the Director of the newly established Office of Oncology Drug Products in CDER’s Office of New Drugs, currently located in Rockville, MD.  The Office Director will have the unique opportunity to establish a cross-cutting oncology program that has the potential to significantly impact public health and the future of cancer therapy.  The Director of the Office of Oncology Drug Products will have responsibility for the regulatory oversight and approval of both drug and biologic products to treat, diagnose, and prevent cancer.  The product scope will also include hematologic therapies, radiation protection agents, medical imaging drugs, and radiographic agents used to diagnose, monitor, and treat cancer and other diseases.

In addition to broad responsibilities for cancer drug development, the Director will coordinate and direct a cross-cutting FDA Oncology Program, including an Agency-wide Oncology Coordinating Committee to insure proactive and consistent policies and approaches to the development of anticancer therapies. The Director will coordinate this effort with other important groups, including the National Cancer Institute, oncology professional societies, and academic centers of cancer excellence.

The ideal candidate will be an oncologist or hematologist-oncologist who is a nationally recognized oncology expert with knowledge of the basic science of drug development and translational research.  This individual should possess the ability to lead large groups of highly skilled individuals and should have excellent interpersonal skills and the ability to build consensus, coupled with an innovative and forward-thinking viewpoint.  Finally, this individual will have a strong commitment to public health.

For more information on this exciting opportunity, please see our recruitment advertisement in the October 15th issue of the Journal of Clinical Oncology, or you may view the advertisement online at http://careercenter.jco.org.

Current permanent Federal employees in competitive positions or former employees with reinstatement eligibility may view and apply directly to this position at the Office of Personnel Management (OPM) Website.

For more information on the new Office of Oncology Drug Products, please see FDA News: FDA to Establish New Cancer Office and Program: Changes Designed to Improve Efficiency and Consistency of Cancer Product Reviews

Back to Top     Back to Careers

Date created: October 6, 2004, updated October 7, 2004

horizonal rule